ClinicalTrials.gg
CompletedNCT06863636PRECEDENTUpdated Oct 23, 2026

Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation

A Phase 3 interventional study of Celecoxib + Acetaminophen and Celecoxib + Acetaminophen in Joint Pain, Knee Osteoarthritis and Hip Osteoarthritis, sponsored by Laboratorios Silanes S.A. de C.V.. Completed at 1 site in Mexico. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Laboratorios Silanes S.A. de C.V. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2024, registered Mar 2025).
Updated Oct 23, 2026Now CompletedEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

This is a Phase III, longitudinal, multicenter, randomized, double-blind clinical trial designed to evaluate the efficacy and safety of a fixed-dose combination of celecoxib and acetaminophen compared to celecoxib monotherapy for the treatment of pain associated with acute exacerbations of osteoarthritis.

Read the detailed description

Researchers will evaluate the efficacy and safety of a fixed-dose combination of celecoxib and acetaminophen compared to celecoxib monotherapy for the treatment of pain in patients with osteoarthritis experiencing an acute exacerbation over a 6-week follow-up period. Adverse events related to the study interventions will be recorded throughout the follow-up phase.

Participants will:

Be randomized into one of three intervention groups (A, B, or C).

Attend five scheduled clinic visits (Day 0, and Weeks 1, 2, 4, and 6 of follow-up).

Be permitted to take 500 mg of naproxen as rescue medication, if needed, with prior authorization from the principal investigator.

02

Conditions studied

  • Joint Pain
  • Knee Osteoarthritis
  • Hip Osteoarthritis

Keywords

  • Joint pain
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Acute pain
03

In context

Arthralgia

277 studies on the registry are indexed under Arthralgia; 54 are open to participants now.

This study's enrollment of 231 is above the median of 73 across 218 interventional studies indexed under Arthralgia.

Browse Arthralgia studies →

Lead sponsor

Laboratorios Silanes S.A. de C.V. is the lead sponsor of 45 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily agrees to participate in the study and provides written .
  • Prior diagnosis of knee or hip osteoarthritis based on clinical criteria (according to the American College of Rheumatology (ACR) criteria described in Annex 5).
  • Pain in the affected joint with exacerbation lasting no more than 3 weeks.
  • Patient reports moderate to severe pain intensity (VAS ≥ 40 mm).
  • For women of (a woman is considered fertile after menarche and until unless permanently sterile), they must agree to use at least ONE of the following methods during the study:

Barrier methods: diaphragm, cervical cap, male condom, female condom, spermicide foam, sponge, or film.

Hormonal methods: combined oral contraceptives, injectable contraceptives, subdermal implant, contraceptive patch.

Intrauterine device (IUD): copper or silver IUD, Levonorgestrel intrauterine system (IUS), and/or combinations of the above as deemed acceptable by the physician.

Women are considered not of childbearing potential if they meet at least ONE of the following criteria:

Postmenopausal. Premenopausal woman with at least ONE of the following: hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.

Male subjects must agree to use a male condom as a contraceptive method during the study.

  • At the discretion of the Principal Investigator (PI) or treating physician, the subject has an indication for treatment with the product and may derive clinical benefit from it.

Exclusion criteria

Exclusion Criteria:

  • Intolerance or allergy to the product or any of its components (as reported in the medical history and patient interview).
  • Participation in another clinical study involving an investigational treatment or participation in one within the last two weeks prior to the study start.
  • Potential study bias due to employment or relationship with the research center, sponsor, or being part of a vulnerable population.
  • Medical conditions affecting prognosis that prevent outpatient management, to be evaluated by the Principal Investigator for subject inclusion relevance.
  • History of advanced, severe, progressive, or unstable disease of any kind that may interfere with efficacy and safety assessments or pose a special risk to the patient.
  • Medical to the investigational product.
  • History of allergic reaction to NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Acetaminophen, or known to any formulation components.
  • Significant gastrointestinal disorders, such as gastric ulcers, Crohn's disease, ulcerative colitis, or gastrointestinal bleeding.
  • Prior opioid treatment within the last five days, as reported in the medical history.
  • History of treatment failure with COX-2 selective inhibitors, as documented in the medical history.
  • History of chronic somatic pain unrelated to knee or hip osteoarthritis (e.g., fibromyalgia, disease, or Paget's disease).
  • History of alcohol or drug abuse within the past year.
  • Current treatment with NSAIDs, including COX-2 inhibitors, within the last 72 hours before signing (except for aspirin used for cardioprotective purposes).
  • History of arthroscopy, viscosupplementation, or intra-articular use in the last three months.
  • Previous surgery on the affected joint within the last six months.
  • Major trauma in the affected joint within the last three weeks.
  • History of chronic liver failure ( A, B, or C).
  • History of acute or severe renal failure ( \<30 ml/min/1.73 m²), as reported in the medical history.
  • Significant coagulation disorders (e.g., Von Willebrand disease, hemophilia, vitamin K deficiency) or current use of anticoagulants.

Oncologic patients (except basal cell carcinoma) or those with severe illnesses that, according to the investigator, have a poor prognosis or a of less than one year, including severe mental illness.

  • Patients with symptoms suggestive of active COVID-19 infection (e.g., fever, cough, dyspnea) and/or contact within the last 14 days with a suspected or confirmed COVID-19 patient.
  • Positive pregnancy test, pregnant women, those currently breastfeeding, or those planning pregnancy during the study period.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
231 participants (actual)

Study arms

  • Experimental
    Celecoxib+Acetaminophen

    Administered orally, 1 tablet a day during 6 weeks

    Drug: Celecoxib + Acetaminophen

  • Experimental
    Celecoxib + Acetaminophen

    Administered orally, 1 tablet a day during 6 weeks

    Drug: Celecoxib + Acetaminophen

  • Active comparator
    Celecoxib

    Administered orally, 1 capsule a day during 6 weeks

    Drug: Celecoxib

Interventions

  • DrugCelecoxib + Acetaminophen

    Drug pages: Celecoxib · Acetaminophen

    One tablet of 200 mg / 200 mg a day

    Also known as: Cele + Ace

  • DrugCelecoxib + Acetaminophen

    Drug pages: Celecoxib · Acetaminophen

    One tablet of 200 mg / 500 mg a day

    Also known as: Cele + Ace

  • One capsule of 200 mg a day

    Also known as: Cele

06

What researchers measure

Primary outcomes

  1. Comparison of the proportion of patients in each treatment group who, based on the baseline assessment, achieved a response according to the OMERACT-OARSI criteria at Weeks 1, 2, 4, and 6 of follow-up.

    OMERACT (Outcome Measures in Rheumatology) and OARSI (Osteoarthritis Research Society International) jointly developed a core outcome set (COS) for clinical trials in hip and knee osteoarthritis. This COS includes four key domains that should be assessed in all trials: pain, physical function, patient global assessment, and- for studies lasting one year or more-joint imaging. In this study, patients will be evaluated by the researcher at follow-up visits occurring at Weeks 1, 2, 4, and 6.

    Time frame: 6 weeks

  2. Number of participants Number of participants reporting treatment-related adverse events, as recorded in the patient diary.treatment-related adverse events through the patient's diary record.

    To describe the frequency, intensity, and causality of adverse events occurring during the clinical trial, stratified by treatment group. Adverse events will be documented by participants in their patient diaries. Each reported event will be monitored and followed up at the discretion of the investigator.

    Time frame: 6 weeks

Secondary outcomes

  1. To analyze the mean change in pain scores, as measured by the WOMAC questionnaire, at Weeks 1, 2, 4, and 6 compared to baseline, by treatment group.

    The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a disease-specific questionnaire designed to assess physical function, pain, and stiffness in individuals with hip or knee osteoarthritis, based on their experiences over the past 48 hours. In this study, patients will be assessed by the investigator at Weeks 1, 2, 4, and 6 of follow-up.

    Time frame: 6 weeks

  2. To analyze the mean change in pain intensity, as measured by the Visual Analog Scale (VAS), at Weeks 1, 2, 4, and 6 compared to baseline, stratified by treatment group.

    The Visual Analog Scale (VAS) for pain is a straight line where one end represents no pain and the other represents the worst pain imaginable. The investigator will administer the VAS at each visit to assess the patient's pain intensity. At the end of the clinical trial, the percentage change in pain scores will be calculated and compared across treatment groups.

    Time frame: 6 weeks

  3. Comparison of the proportion of subjects in each treatment group who achieve a reduction of ≥30% in pain intensity, as measured by the Visual Analog Scale (VAS), at Weeks 1, 2, 4, and 6 compared to baseline.

    The Visual Analog Scale (VAS) for pain is a unidimensional measurement instrument consisting of a straight line anchored by descriptors, with one end indicating "no pain" and the other representing "the worst pain imaginable." The investigator will administer the VAS at each study visit to evaluate changes in pain intensity. The proportion of patients achieving a pain reduction of more than 30% from baseline will be documented and compared among treatment groups at Weeks 1, 2, 4, and 6.

    Time frame: 6 weeks

  4. To analyze the difference in SF-36 quality of life questionnaire scores at six weeks after the initiation of the intervention, compared to baseline, by treatment group.

    The Short Form-36 (SF-36) is a generic health survey comprising 36 items designed to measure self-reported Health-Related Quality of Life (HRQoL). It evaluates multiple domains of physical and mental health and generates summary scores for both physical and mental components. In this study, the SF-36 questionnaire will be administered to each patient at baseline and again at Week 6 of follow-up.

    Time frame: 6 weeks

Other outcomes

  1. To report the treatment adherence rate, expressed as a percentage, for each intervention group.

    Therapeutic adherence will be defined by the principal investigator. Adherence to treatment will be considered adequate if the patient has taken ≥80% of the prescribed doses by the time of the corresponding evaluation.

    Time frame: 6 weeks

  2. To describe the proportion of subjects experiencing therapeutic failure during the study, stratified by treatment group.

    Therapeutic failure will be defined by the principal investigator following a medical evaluation. The definition requires the presence of all the following criteria: (1) a change in pain intensity of less than 10 mm on the Visual Analog Scale (VAS), or an increase in VAS score compared to baseline; (2) adherence to treatment of ≥80%; (3) a dosing regimen of every 12 hours (i.e., subjects with dose escalation) maintained for at least 7 days; and (4) absence of comorbidities that could contribute to increased pain, such as new trauma or falls.

    Time frame: 6 weeks

  3. To report the proportion of patients requiring dose escalation during the follow-up period, stratified by treatment group.

    At each study visit, dose escalation (one tablet or capsule every 12 hours) may be considered for patients in any of the three treatment arms who meet the following criteria: A decrease of less than 10 mm, no change, or an increase in pain intensity on the Visual Analog Scale (VAS) compared to the previous visit. Treatment adherence of ≥80%.

    Time frame: 6 weeks

07

Study locations

1 site
  • Laboratorio Silanes, S.A. de C.V.
    Mexico City, Mexico City 11000, Mexico
08

References and documents

Publications

  • Ebrahimzadeh MH, Makhmalbaf H, Birjandinejad A, Keshtan FG, Hoseini HA, Mazloumi SM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in Persian Speaking Patients with Knee Osteoarthritis. Arch Bone Jt Surg. 2014 Mar;2(1):57-62. Epub 2014 Mar 15. PubMed 25207315 ↗
  • Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P. Celecoxib for osteoarthritis. Cochrane Database Syst Rev. 2017 May 22;5(5):CD009865. doi: 10.1002/14651858.CD009865.pub2. PubMed 28530031 ↗
  • Krieckaert CL, van Tubergen A, Gehin JE, Hernandez-Breijo B, Le Meledo G, Balsa A, Bohm P, Cucnik S, Elkayam O, Goll GL, Hooijberg F, Jani M, Kiely PD, McCarthy N, Mulleman D, Navarro-Compan V, Payne K, Perry ME, Plasencia-Rodriguez C, Stones SR, Syversen SW, de Vries A, Ward KM, Wolbink G, Isaacs JD. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023 Jan;82(1):65-73. doi: 10.1136/annrheumdis-2022-222155. Epub 2022 May 12. PubMed 35551063 ↗
  • Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012 Apr;64(4):465-74. doi: 10.1002/acr.21596. PubMed 22563589 ↗
  • Busse JW, Bartlett SJ, Dougados M, Johnston BC, Guyatt GH, Kirwan JR, Kwoh K, Maxwell LJ, Moore A, Singh JA, Stevens R, Strand V, Suarez-Almazor ME, Tugwell P, Wells GA. Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop. J Rheumatol. 2015 Oct;42(10):1962-1970. doi: 10.3899/jrheum.141440. Epub 2015 May 15. PubMed 25979719 ↗
  • Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, Callahan L, Copenhaver C, Dodge C, Felson D, Gellar K, Harvey WF, Hawker G, Herzig E, Kwoh CK, Nelson AE, Samuels J, Scanzello C, White D, Wise B, Altman RD, DiRenzo D, Fontanarosa J, Giradi G, Ishimori M, Misra D, Shah AA, Shmagel AK, Thoma LM, Turgunbaev M, Turner AS, Reston J. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020 Feb;72(2):220-233. doi: 10.1002/art.41142. Epub 2020 Jan 6. PubMed 31908163 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Oct 2025, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 7, 2025
StartActual
Sep 9, 2024
Primary completionActual
Oct 30, 2025
CompletionActual
Nov 30, 2025
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 23, 2026
Sites
1 site added, 1 site removed
Show site
  • Laboratorio Silanes, S.A. de C.V. · Mexico City, Mexico
Show 1 removed
  • Laboratorio Silanes, S.A. de C.V. · Mexico City, Mexico
Oct 23, 2026
Interventions
Added Drug: Celecoxib + Acetaminophen; removed Drug: Celecoxib + Acetaminohen·Drug: Celecoxi + Acetaminophen
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Laboratorio Silanes, S.A. de C.V. · Mexico City, Mexico
    Show 1 removed
    • Laboratorio Silanes, S.A. de C.V. · Mexico City, Mexico
    Interventions Added Drug: Celecoxib + Acetaminophen; removed Drug: Celecoxib + Acetaminohen·Drug: Celecoxi + Acetaminophen
    + 4 other changes: index terms, verification date, date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06863636
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Sep 9, 2024
Primary completion
Oct 30, 2025
Completion
Nov 30, 2025
Last update
Oct 23, 2026

Study contacts

Isabel E Rucker-Joerg, MD
principal investigator · Clinical Research Institute S.C.
Ivonne A Torres-Quiroz, MD
principal investigator · Unidad de Medicina Especializada SMA
Adelfia Urenda-Quezada, MD
principal investigator · Servicios Avanzados de Investigación Médica Mediadvance, S.C.
Martha V Chavira-Flores, MD
principal investigator · Consultorio Médico "Dr. Rodrigo Suárez Otero"
Rodrigo Suarez-Otero, MD
principal investigator · IMACEN S.A. de C.V.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Celecoxib · Acetaminophen

Start the discussion